Literature DB >> 30443908

The prevalence, alloimmunization risk factors, antigenic exposure, and evaluation of antigen-matched red blood cells for thalassemia transfusions: a 10-year experience at a tertiary care hospital.

Amornrat V Romphruk1, Piyapong Simtong2, Chalawan Butryojantho1, Ratchadaporn Pimphumee1, Ninnate Junta1, Supawadee Srichai1, Patcharee Komvilaisak3, Chintana Puapairoj1.   

Abstract

BACKGROUND: Hemoglobin E-β0 thalassemia and homozygous β0 -thalassemia are the most common chronic transfusion-dependent thalassemias in Thailand. Patients with these conditions can experience clinical complications such as RBC alloimmunization. In this study we aimed to determine the prevalence, alloimmunization risk factors, antigenic exposure, and evaluation of antigen- (C, c, E, e, Mia ) matched RBC transfusion. STUDY DESIGN AND METHODS: Thalassemia patients were recruited from a tertiary care hospital for 10 years from 2008 to 2017. The medical records of transfusion history were reviewed for red cell phenotype both of patients and donors, number of units transfused, and type of alloantibodies.
RESULTS: A total of 383 thalassemia patients were identified (178 males and 205 females). The frequency of RBC alloantibodies was 19.3%. Some patients tested positive for more than one antibody type. Autoantibodies were detected in nine individuals. Anti-E (49 [39.5%]), anti-Mia (24 [19.4%]), and anti-c (19 [15.3%]) were the most common antibodies detected. A high rate of alloimmunization was found in splenectomized patients. Risk of alloimmunization increased when more total units of blood had been transfused. A trend toward low alloimmunization rates was noted in the antigen-matched RBC group, where 3.5% (5/143) of patients were alloimmunized. Anti-E and anti-Mia , which may be naturally occurring, were identified in this group.
CONCLUSION: Thai patients are more prone to develop antibodies against the Rh and Mia than to the Kell blood group antigens. Provision of at least antigen-matched (C, c, E, e, Mia ) RBCs appears to improve the efficacy of transfusion in thalassemia patients.
© 2018 AABB.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30443908     DOI: 10.1111/trf.15002

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  3 in total

1.  Red blood cell alloimmunization and other transfusion-related complications in patients with transfusion-dependent thalassemia: A multi-center study in Thailand.

Authors:  Nattiya Teawtrakul; Duantida Songdej; Chattree Hantaweepant; Adisak Tantiworawit; Supanun Lauhasurayotin; Kitti Torcharus; Pornpun Sripornsawan; Pranee Sutcharitchan; Pacharapan Surapolchai; Patcharee Komvilaisak; Supawee Saengboon; Bunchoo Pongtanakul; Pimlak Charoenkwan
Journal:  Transfusion       Date:  2022-08-20       Impact factor: 3.337

2.  A study of red blood cell alloimmunization and autoimmunization among 200 multitransfused Egyptian β thalassemia patients.

Authors:  Amal El-Beshlawy; Alshymaa Ahmed Salama; Mohamed Roshdy El-Masry; Noha M El Husseiny; Asmaa M Abdelhameed
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

3.  Study of Frequency and Characteristics of Red Blood Cell Alloimmunization in Thalassemic Patients: Multicenter Study from Palestine.

Authors:  Adham Abu Taha; Ahmad Yaseen; Sa'd Suleiman; Omar Abu Zenah; Hammam Ali; Rania Abu Seir; Khaled Younis
Journal:  Adv Hematol       Date:  2019-11-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.